Fresenius Medical Care : Q2 2018 preview: reported EBIT boosted by one-time gain from Sound divestment
>We expect reported Q2 18e sales down 6% yoy (lfl +4% in cc) - Fresenius Medical Care (FME) is due to publish its Q2 2018 figures on 31 July. We expect reported sales down c.6% yoy to € 4,209m (Q2 17: € 4,471m) mainly due to FX-headwinds, IFRS 15 adjustment (c.3pp of growth), and lower revenue in Care Coordination due to the sale of Shiel at the end of 2017 (3pp of growth). Adjusted for these effects, we estimate c.4% lfl growth in constant currencies (cc). Thanks to...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.